Christopher Barnes, D.O.
NPI 1982018933 · Endocrinology, Diabetes & Metabolism Physician · Elmira, NY
Enrolled with Medicare as Practitioner - Endocrinology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1982018933
- Entity type
- Individual
- Primary specialty
- Endocrinology, Diabetes & Metabolism PhysicianAllopathic & Osteopathic Physicians
- Credential
- D.O.
- Sex
- Male
- Sole proprietor
- No
- License
- 298004 (NY)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
12 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
817 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 420 | $92 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 243 | $114 |
| Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin With Interpretation and Report95251 | 77 | $33 |
| Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin With Interpretation and Report95251 | 48 | $33 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More99204 | 16 | $120 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 84 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Levothyroxine Sodium | 1,166 | 240 |
| Semaglutidebrand: Ozempic | 831 | 145 |
| Empagliflozinbrand: Jardiance | 458 | 97 |
| Insulin Glargine,hum.rec.anlogbrand: Lantus Solostar | 352 | 105 |
| Metformin Hclbrand: Metformin Hcl Er | 333 | 75 |
| Dulaglutidebrand: Trulicity |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$50 across 2 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2014-06-18
- Last updated
- 2020-11-20
- Certified
- 2020-11-20
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.